Provided by Tiger Trade Technology Pte. Ltd.

Esperion Therapeutics

2.77
+0.00500.18%
Volume:891.87K
Turnover:2.47M
Market Cap:710.08M
PE:-25.34
High:2.80
Open:2.71
Low:2.66
Close:2.76
52wk High:4.18
52wk Low:0.6925
Shares:256.81M
Float Shares:237.00M
Volume Ratio:0.40
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1091
EPS(LYR):-0.1091
ROE:97.76%
ROA:9.30%
PB:-2.35
PE(LYR):-25.34

Loading ...

Get an Lp(a) test - and 3 other things you must do now for heart health

Dow Jones
·
Mar 19

Esperion to present two CLEAR Outcomes analyses at ACC 2026 Annual Scientific Session

Reuters
·
Mar 17

Esperion says bempedoic acid receives recommendations in ACC/AHA Guideline

TIPRANKS
·
Mar 16

Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

GlobeNewswire
·
Mar 16

Esperion Therapeutics Is Maintained at Market Outperform by Citizens

Dow Jones
·
Mar 13

Esperion price target raised to $5 from $4 at Citizens

TIPRANKS
·
Mar 13

HLS Therapeutics Inc. publishes 2026 annual report

Reuters
·
Mar 13

Esperion Therapeutics Flags Material Weakness in Financial Controls, Raising Reporting and Regulatory Risks

TIPRANKS
·
Mar 12

Piper Sandler Sticks to Their Buy Rating for Esperion (ESPR)

TIPRANKS
·
Mar 11

Esperion Therapeutics: Strong 2025 Execution, Expanding Cardiometabolic Platform, and Vision 2040 Underpin Buy Rating

TIPRANKS
·
Mar 10

BUZZ-Esperion falls after quarterly results miss estimates

Reuters
·
Mar 10

Esperion Therapeutics Shares Gain 2.5% After Co Swings to Q4 Profit

THOMSON REUTERS
·
Mar 10

Shares of Esperion Therapeutics up 7.5% Premarket After Co Swings to Q4 Profit

THOMSON REUTERS
·
Mar 10

Esperion Therapeutics Q4 revenue jumps 144% on US product strength

Reuters
·
Mar 10

Earnings Flash (ESPR) Esperion Therapeutics Posts Q4 EPS $0.22, vs. FactSet Est of $0.27

MT Newswires Live
·
Mar 10

Esperion Therapeutics Q4 EPS $0.22 Misses $0.30 Estimate, Sales $168.446M Miss $174.519M Estimate

Benzinga
·
Mar 10

BRIEF-Esperion Therapeutics Q4 Product Sales USD 43.723 Million

Reuters
·
Mar 10

Esperion Therapeutics Q4 Operating Expenses USD 83.213 Million

THOMSON REUTERS
·
Mar 10

Esperion Therapeutics Q4 Operating Income USD 85.233 Million VS. Ibes Estimate USD 98.7 Million

THOMSON REUTERS
·
Mar 10

Esperion Therapeutics Inc - Expects FY2026 Operating Expenses of $225 Mln-$255 Mln

THOMSON REUTERS
·
Mar 10